natgillin/translations-raw huggingface dataset:
Formulations suitable for rectal administration are preferably presented as unit-dose suppositories, with a solid based carrier, such as cocoa butter, and may include a salicylate. 
Formulacije pogodne za rektalnu primjenu po mogućnosti se prezentira u obliku supozitorija kao jedinica doze, uz čvrstu podlogu, poput kakao-maslaca, a mogu uključivati i salicilat.
further the outer shell (OS) is placed in a work environment which is of higher temperature than after the cooling causing the temperatures inside the inner rotors cavities to rise due to the radiation emitted by the environmental thermal energy, received from the outer shell (OS) through the vacuum cavity (60) and the temperature of the insulated areas rise much less than the temperatures of the non-insulated areas; 
- - vanjsko kućište (SK) se zatim postavlja u radnu sredinu koja se odlikuje višom temperaturom u odnosu na temperaturu postignutu nakon perioda hlađenja, na taj način dovodeći do porasta temperature fluida u šupljinama unutarnjeg rotora i to na račun toplinske energije koja se zračenjem prenosi sa ambijentalne okoline i preuzimanja te iste energije preko vanjskog kućišta i vakuum šupljine (60); pri tome, temperatura termički izoliranih dijelova sistema raste mnogo sporije od temperature neizoliranih dijelova sistema;
The antidiabetic agent may also preferably be a sulfonyl urea such as glyburide (also known as glibenclamide), glimepiride (disclosed in U.S. Pat. No. 4,379,785), glipizide, gliclazide or chlorpropamide, other known sulfonylureas or other antihyperglycemic agents which act on the ATP-dependent channel of the beta-cells, with glyburide and glipizide being preferred, which may be administered in the same or in separate oral dosage forms. 
Antidijabetesni agensi mogu također poželjno biti sulfonil urea kao što je gliburid (također poznat kao glibenklamid), glimepiridin (prikazan u U.S. Patentnom br. 4,379,785), glipizid, gliklazid ili klorpropamid, druge poznate sulfoniluree ili drugi antihiperglikemijski agensi koji djeluju na ATP-ovisne kanale beta stanica, pri čemu su poželjni gliburid i glipizid, koji se mogu unositi u istim ili odvojenim oblicima oralnih doza. Oralni antidijabetesni agensi mogu također biti inhibitori glukozidaze kao što je akarbos (prikazan u U.S.Patentnom br. 4,904,769) ili miglitol (prikazan u U.S.Patentnom br. 4,639,436), koji se mogu unositi u istim ili u odvojenim oblicima oralnih doza.
The pharmaceutical composition for use according to claim 12, wherein the cancer is cancer of the buccal cavity and pharynx, cancer of the digestive tract, cancer of the colon, rectum, and anus, cancer of the respiratory tract, breast cancer, cancer of the cervix uteri, vagina, and vulva, cancer of the uterine corpus and ovary, cancer of the male genital tract, cancer of the urinary tract, cancer of the bone and soft tissue, and Kaposi sarcoma, melanoma of the skin, eye melanoma, and non-melanoma eye cancer, cancer of the brain and central nervous system, cancer of the thyroid and other endocrine glands, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and myeloma, such as renal cancer, colorectal cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, gastric cancer, GIST or glioblastoma. 
Farmaceutski sastav za uporabu prema zahtjevu 10, pri čemu je karcinom karcinom usne šupljine i ždrijela, karcinom probavnog trakta, karcinom debelog crijeva, rektuma i anusa, karcinom respiratornog trakta, karcinom dojke, karcinom grlića maternice, vagine i vulve, karcinom tijela maternice i jajnika, karcinom muškog genitalnog trakta, karcinom urinarnog trakta, karcinom kostiju i mekog tkiva, Kaposijev sarkom, melanom kože, melanom oka, nemelanomski karcinom oka, karcinom mozga i središnjeg živčanog sustava, karcinom žlijezde štitnjače i drugih endokrinih žlijezda, Hodgkinov limfom, ne-Hodgkinov limfom ili mijelom, najbolje karcinom bubrega, kolorektalni karcinom, karcinom pluća, karcinom dojke, karcinom gušterače, karcinom prostate, karcinom želuca, gastrointestinalni stromalni tumor (GIST) ili glioblastom.
A ship as claimed in claim 5, characterized in that it comprises a line (137', 137") for conveying the filtrate exiting from the purification device (120', 120") back to the effluent circuit (3', 3") for further purifying the filtrate. 
Brod prema zahtjevu 5, naznačen time da sadrži vod (137', 137") za transport filtrata koji izlazi iz uređaja za pročišćavanje (120', 120") natrag u krug efluenta (3', 3") radi dodatnog pročišćavanja filtrata.
Rf is independently selected from H, F, Cl, Br, CN, OH, C1-5alkyl (optimally substituted with halogen and OH), C3-6 cycloalkyl, and phenyl, or Rf and Rf together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with C1-4alkyl; 
Rf je nezavisno odabrano od H, F, Cl, Br, CN, OH, C1-5alkil (optimalno supstituiran sa halogen i OH), C3-6 cikloalkil, i fenil, ili Rf i Rf zajedno sa atomom dušika za koji su oba vezana formiraju heterociklični prsten po izboru supstituiran sa C1-4alkil grupom;
Calculation of the percentage coverage of the fetal genome 
Datum objave europskog patenta:
The present invention aims at providing a method of production of hot rolled Fe-Si steel sheet comprising the successive steps consisting in: 
Postupak proizvodnje hladno valjanog Fe-S1 čeličnog lima koji sadrži uzastopne korake koji se sastoje od: taljenja čeličnog pripravka koji sadrži masene postotke:
Example 7 was prepared according to the procedure utilized for the preparation of Example 2, replacing isonicotinic acid with thiazole-4-carboxylic acid. 
Farmaceutski pripravak sukladno patentnom zahtjevu 2, naznačen time, da je čvrsti oblik doze tableta.
A compound according to Formula I: wherein M represents the macrolide subunit of the substructure II: wherein R1, R2, R3, R4 and R5 are, chosen independently of each other, from the group consisting of hydrogen, C1-C4alkyl, alkanoyl, alkoxycarbonyl, arylmethoxycarbonyl, aroyl, arylalkyl, alkylsilyl and alkylsilylalkoxyalkyl; 
M predstavlja makrolidnu podjedinicu podstrukture II; gdje R', R', R*, R* i R? se, međusobno neovisno, bira iz skupine koju čine vodik, C,-C,alkil, alkanoil, alkoksikarbonil, arilmetoksikarbonil, aroil, arilalkil, alkilsilil i alkilgililalkoksialkil;
The method of claim 1, wherein the amount of the compound of formula R1SR2 ranges from about 1.0 to about 9.0, from about 2.0 to about 5.0 or from about 2.5 to about 3.5 molar equivalents per molar equivalent of the chlorine-containing reagent. 
Postupak prema zahtjevu 1, naznačen time da je količina spoja formule R;SR> u rasponu od oko 1.0 do oko 9.0, od oko 2.0 do oko 5.0 ili od oko 2.5 do oko 3.5 molarnih ekvivalenata po molarnom ekvivalentu reagensa koji sadrži klor.
p is independently 1 or 2; and 
p je neovisno 1 ili 2; i y je 1, 2 ili 3;
Compound 25 was obtained as a white solid from compound 24 by method A. 
Spoj 25 se dobiva kao bijela krutina iz spoja 24 pomoću postupka A. ju
A glassy lozenge according to claim 2 wherein 55-85 wt % of component (ii) consists of: 
Tableta-pastila prema patentnom zahtjevu 2, naznačena time što se 55-85 mas.% komponente (ii) sastoji od:
A compound of formula I wherein R1 is methyl or ethyl; 
Spoj formule I [image] naznačen time što: je metil ili etil;
Use of a compound according to claim 16 or a composition according to any one of claims 17 to 21 and 24 for the manufacture of a medicament for decreasing food intake. 
Uporaba spoja u skladu s bilo kojim zahtjevom 1 do 11, naznačena time, da se koristi za izradu lijeka za smanjivanje uzimanja hrane.
The combination for use according to anyone of the preceding claims, wherein the subject to be treated has a HbA1 c value in the range of 7% to 10% or/and a fasting plasma glucose concentration of at least 7 mmol/L or/and 2 hours postprandial plasma glucose of at least 11.1 mmol/L. 
Kombinacija namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što subjekt kojeg treba liječiti vrijednost ima HbAlc u rasponu od 7% do 10% ili/i koncentraciju glukoze u plazmi tijekom gladovanja od najmanje 7 mmol/l ili/i koncentraciju glukoze u plazmi 2 sata nakon obroka od najmanje 11,1 mmol/I.
formoterol, or a salt thereof or a solvate of said salt at a dosage in the range from 1 to 25 µg per actuation; 
(b) formoterol ili njegovu sol ili solvat rečene soli u dozi u rasponu od 1 do 25 ug po aktiviranju;
A drug injection device of claim 1, characterized in that the drive means for the piston (29) is attached to the drug syringe mounting component. 
Uređaj za mjektiranje lijeka prema zahtjevu 1, naznačen time što su pogonska sredstva za klip (29) pričvršćena na komponentu za postavljanje štrcaljke za lijek.
The portion capsule according to claim 1, wherein the filter element is a synthetic nonwoven and/or a felt structure. 
Kapsula s porcijom prema jednom od prethodnih zahtjeva, naznačena time da element filtera je netkani materijal i/ili ima strukturu od pusta.
The kit for use as claimed in claim 1 or 2, wherein pharmaceutically acceptable aqueous medium is a buffered physiological saline aqueous solution. 
Farmaceutski komplet za upotrebu kako je prijavljen u patentnom zahtjevu 1 ili 2, naznačeno time da je farmaceutski prihvatljiv vodeni medij puferirana fiziološka vodena otopina kuhinjske soli.
EXAMPLE 23 In Example 23, 154.5 mg tablets including 30 mg Hydromorphone HCl were prepared using high molecular weight polyethylene oxide. 
Postupak prema zahtjevu 30, naznačen time da se oko 100% polietilen oksida visoke molekulske mase rastopi.
The process according to claim 1, wherein said polar solvent is separated from said mixture of solvents by extraction with water. 
Postupak u skladu s prethodnim patentnim zahtjevom, naznačen time što se navedeno polarno otapalo odvaja od navedene smjese otapala ekstrakcijom vodom.
The anti-PRLR Antibody Drug Conjugate (ADC) of claims 28 or 29 wherein the antibody, or antigen-binding portion thereof, comprises at least 3 CDRs selected from a light chain variable domain CDR set (CDR1, CDR2, and CDR3) consisting of SEQ ID NOs: 49, 50, and 51; SEQ ID NOs: 65, 66, and 67; SEQ ID NOs: 79, 80, and 81; and SEQ ID NOs: 92, 93, and 94. 
Anti-PRLR konjugat protutijelo lijek (ADC) prema zahtjevima 28 ili 29 naznačen time da protutijelo, ili njegov dio koji veže antigen, sadrži barem 3 CDR-a koji su odabrani iz skupa varijabilnih domena laganog lanca CDR (CDR1, CDR2, i CDR3) koji obuhvaća SEQ ID NOs: 49, 50, i 51; SEQ ID NOs: 65, 66, i 67; SEQ ID NOs: 79, 80, i 81; i SEQ ID NOs: 92, 93, i 94.
is individually and independently selected from the group consisting of Ser, Thr, Ala and Gly; and/or 
ili Xxx4 se pojedinačno i neovisno bira iz skupine koju čine Ser, Thr, Ala i Gly.
A and X are equal or different independently and are selected from alkyl C3-C10, alkenyl C1-C10, cycloalkyl C1-C7 or any substituted or unsubstituted aryl group; 
R se bira između H, hidroksilne skupine, alkila C,-C,, alkenila C;-C:, cikloalkila Cs-C; ili bilo koje supstituirane ili nesupstituirane arilne skupine;
Suitable short extension linkers can be represented by the amino acid sequence in SEQ ID NO:3. 
Postupak prema zahtjevu 1 ili zahtjevu 2, naznačen time da proširujuća poveznica sadrži SEQ ID NO: 3.
The control method according to claim 13, characterized in that when a vehicle applied with the hybrid drive system for vehicle is in the braking deceleration energy recycling mode, the second motor and/or the first motor perform energy recycling when the vehicle is braking, and in this mode, the first motor and/or the second motor are controlled to generate electricity. 
Postupak upravljanja prema bilo kojem od zahtjeva 13 do 21, naznačena time, da kada je vozilo primijenjeno s hibridnim pogonskim sustavom način rada za recikliranje energije usporavanjem kočnice, drugi motor (3) i/ili prvi motor (2) obavljaju recikliranje energije pri kočenju vozila, a u tom načinu upravljaju prvi motor (2) i/ili drugi motor (3) za generiranje struje.
The receiver according to claim 1, wherein the receiver includes a handle and a spout for easy disposing of the contents. 
Prijemna posuda sukladno patentnom zahtjevu 1 naznačeno time što ta prijemna posuda sadrži dršku (22) 1 grlić (20) za lako odlaganje sadržaja.
The diphenyl sulfide derivative according to claim 1, or a pharmaceutically acceptable salt or hydrate thereof, wherein the compound represented by the general formula (1) is represented by the general formula (1b), (In the formula (1b) Xa represents an oxygen atom or -CH2-, and R1, R2, and Y are as defined above) . 
Derivat difenil-sulfida u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol ili hidrat, naznačen time što je spoj prikazan općom formulom (1) prikazan općom formulom (1b), [image], gdje u formuli (1b) Xa predstavlja atom kisika ili -CH2-, a R1, R2 i Y su definirani kao gore.
After alcohol treatment, the cells were disrupted by homogenization. 
Nakon obrade alkoholom, stanice su razorene pomoću homogenizacije.
The DNA-targeting RNA provides target specificity to the complex by comprising a nucleotide sequence that is complementary to a sequence of a target DNA. 
(i) segment koji cilja na DNK 1 koji obuhvaća nukleotidnu sekvencu koja je komplementarna sekvenci u ciljanoj DNK, 1
homogenized, after which by means of the device 1 the mixture is: 
- < homogenizira, nakon čega se mješavina pomoću navedenog uređaja:
In addition, compounds of formula (III) wherein R3 represents a fluorine atom may be obtained by analogy to the method described in Tetrahedron Letters, Vol.30,N°45,pp 6113-6116,1989. 
Uz to, spojeve formule (III), gdje R3 predstavlja atom fluora, može se dobiti postupkom analognim onom opisanom u Tetrahedron Letters, sv. 30, br. 45, str.
The alkyd polymer has a preferred cobalt content of 1 to 2.5% by weight and/or a mean molecular weight of more than 4000. 
Spoj prema zahtjevu 1, čija je značajka to što alkidni polimer ima sadržaj kobalta od 1 do 2,5 % po masi.
a single nucleic acid molecule comprising said adenovirus E1A coding sequence, said adenovirus E1B-19K coding sequence, and said adenovirus E1B-55K coding sequence, wherein at least two of said adenovirus E1A coding sequence, said adenovirus E1B-19K coding sequence, and said adenovirus E1B-55K coding sequence are separated by at least 8 kb; and two or more nucleic acid molecules together comprising the E1A and E1B-19K and E1B-55K coding sequences wherein said E1A and at least one of the E1B coding sequences are separated by at least 8 kb when said two or more nucleic acid molecules would form a single molecule by end-to-end joining before integrating into the precursor cell's genome. 
Postupak pripreme stanice koja ima adenovirus EIA i E1B-I9K i E1B-55K kodirajuće sekvence integrirane u njezin genom, naznačen time da postupak sadrži korake uvođenja u prekursorsku stanicu: jednostruke molekule nukleinske kiseline koja sadrži ELA 1 E1B-19K i El B-55K kodirajuće sekvence, pri čemu navedena E1A 1 barem jedna od E1B kodirajućih sekvenci su odvojene sa barem 8 kb; ili dvije ili više molekula nukleinske kiseline sadrži ELA 1 E1B-19K 1 E1B-55K kodirajuće sekvence pri čemu navedena E1A 1 barem jedna od E1B kodirajućih sekvenci su odvojene sa barem 8 kb kada bi navedene dvije ili više molekula nukleinske kiseline mogle tvoriti jednostruku molekulu spajanjem kraja sa krajem.
The use according to any of the preceding claims, where dose a is below the pharmaceutically effective pain treating dose of tapentadol. 
Lijek prema bilo kojem patentnom zahtjevu od 8 do 12, naznačen time da je doza a ispod farmaceutski djelotvorne doze tapentadola za liječenje boli.
The pharmaceutical composition of claim 31 for use as a medicament. 
Farmaceutska kompozicija iz patentnog zahtjeva 10 za primjenu kao lijek.
The said mineral matter used in the method of the invention preferentially has a percentage by weight of particles having a diameter of less than 2 um, measured by a Sedigraph™ 5100, of between 5% and 90%, and more preferentially between 10% and 60% at the supply of the air classifier in step d). 
Postupak prema jednom od zahtjeva 1 do 22, naznačen time da navedeni mineralni materijal ima težinski postotak čestica koje imaju promjer od manje od 2 pm, mjeren sa uređajem Sedigraph"M 5100, od između 5% 1 90%, poželjno između 10% 1 60% na ulazu razvrstavanja pomoću zraka iz koraka d).
The combination for use as claimed in any one of claims 1 to 3, wherein about 0.05 mg/ml to about 7.0 mg/ml of the ((2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate are applied with about 1 to 2 drops of 2.5 mg/ml of the non-selective beta-adrenergic receptor blocker to an eye of the subject from 1 to 4 times daily. 
Kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, pri čemu se otprilike 0.05 mg/mL do otprilike 7.0 mg/mL ((2R,3$,4R,5R)-5-(6-(ciklopentilamino)-9H-purin-9-il)-3,4-dihidroksitetrahidrofuran-2-il)metil nitrata primjenjuje s otprilike 1 do 2 kapi 2.5 mg/mL neselektivnog blokatora beta-adrenergičkog receptora u oko subjekta 1 do 4 puta na dan.
The conjugate may also be mixed with further antigens. In one embodiment the further antigens comprise at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 S. pneumoniae saccharides selected from the group consisting of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačen time što uključuje dodatni korak miješanja konjugata s dodatnim antigensom, gdje dodatni antigeni može uključivati u najmanju ruku 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 ili 20 S. pneumoniae saharide, koji se biraju iz skupine koju čine 1, 2, 3, 4,5, 6A, 6B, TF, 8, ON, 9V, 10A, IA, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F i 33F.
2, that the mass flow is proportional to the feed speed and to the section area SB of the slab. 
Napominje se, s obzirom na Sliku 2, da je maseni protok proporcionalan brzini ulijevanja i dijelu presjeka Sp slaba.
The ZFP of claim 2, wherein the ZFP is a zinc finger nuclease (ZFN) that cleaves the EPSPS target genomic region of interest, said ZFN comprising one or more engineered zinc finger binding domains and a nuclease cleavage domain and further wherein the ZFN optionally cleaves one or more EPSPS paralogous or orthologous gene sequences comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 10-14 or any sequence having at least about 80-100% sequence identity thereto. 
ZFP prema zahtjevu 2, naznačen time, da ZFP je nukleaza cinkovih prstiju (ZFN) koja cijepa ciljano genomsko područje od interesa EPSPS, dok ZFN sadrži jednu 1li više tehnološki konstruiranih domena za vezanje cinkovih prstiju i domenu cijepanja nukleaze te nadalje time, da ZNF opcijski cijepa jednu ili više paralognih ili ortolognih genskih sekvenci EPSPS koje obuhvaćanju nukleotidnu sekvencu odabranu iz skupine koju čine sekvence od SEQ ID NO:10 do SEQ ID NO:14 ili bilo koja sekvenca s najmanje oko 80-100 % identiteta navedenih sekvenci.
The compound according to claim 6 or a pharmaceutically acceptable salt thereof, wherein R1 is OR or SR and R is an isopropyl group, a isobutyl group or a neopentyl group. 
Spoj prema patentnom zahtjevu 6 ili njegova farmaceutski prihvatljiva sol, naznačen time što R; je OR ili SR 1 R je izopropilna skupina, izobutilna skupina ili neopentilna skupina.
Cholesterol levels were measured at the 24-hour trough level on day 11. 
Razine kolesterola mjerene su tijekom 24 sata 11. dana.
In preferred embodiments, the inventive method may also comprise in step c) that during each of the multiple determinations of the inherent system value FA under the same temperature or concentration conditions, additionally a basic color value FB of the composition is determined without passage through the system and is correlated with the respective value of FA in order to obtain a general correlation between FB and FA that becomes more and more accurate over time in an iterating manner. 
Postupak u skladu s patentnim zahtjevom 2 ili 3, naznačen time, da se u koraku c) tijekom svakog od višestrukih određivanja inherentne sistemske vrijednosti Fa pod istom temperaturom ili koncentracijskim uvjetima, dodatno utvrđuje osnovna boja vrijednosti Fg pripravka bez prolaska kroz sustav koji se čisti 1 koji je u korelaciji s odgovarajućom vrijednošću F, kako bi se dobila opća korelacija između Fg i Fa.
The compound or a pharmaceutically acceptable acid addition salt thereof according to [1], which is a compound selected from the following compounds or a pharmaceutically acceptable acid addition salt thereof: 
Spoj prema zahtjevu 1, naznačen time što se bira od sljedećih spojeva ili njihove farmaceutski prihvatljive kisele adicijske soli:
reacting the compound of Formula XLVII with a compound of Formula XIII to give a compound of Formula XLVIII; 
HM Formula XIII čime se dobiva spoj Formule XLVIII: reakciju spoja Formule XLVIII sa spojem Formule XV:
Combination therapy use of compounds of the invention 
Datum objave europske prijave patenta:
The underlayment of claim 1, wherein said first protrusion (2a) and said second protrusion (2a) are formed from said base material (6). A floor assembly, comprising: 
Podloga u skladu s patentnim zahtjevom 1, naznačena time što su navedena prva izbočina (2a) i navedena druga izbočina (24) načinjene od navedenog osnovnog materijala (6).
One of the biggest problems with freshly harvested pineapples is weight loss during storage and distribution, Four fresh pineapples that had no coating were used as controls and four pineapples and crowns of the fruit were coated with a 5% emulsion as in example 1. 
Jedan od najvećih problema sa svježe ubranim ananasima je gubitak težine u toku čuvanja i distribucije. Četiri svježa ananasa bez ovojnice korišteni su kao kontrole i četiri ananasa i krune voća obloženi su sa 5% emulzijom kao u primjeru 1.
The method of claim 12, wherein the subject is selected from the group consisting of a subject having HS at Hurley Stage II or III, a subject having an AN count of greater than or equal to 3 at baseline, a subject who is female, a subject who is over 40 years old, a subject who is a smoker, or any combination thereof. 
Anti-TNFa protutijelo za uporabu prema bilo kojem od zahtjeva 1-9, naznačeno time, da se subjekt bira iz skupine koja se sastoji od subjekta koji ima početni broj AN veći ili jednak 3, subjekta koji je ženska osoba, subjekta koji je stariji od 40 godina, subjekta koji je pušač, 1li bilo koje od njihovih kombinacija.
A method according to claim 1, further comprising the concentrator transmitting a start time and an end time to the one remote meter requesting transmission of utility consumption related data from said start time to said end time. 
Metoda prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu sabirnik (C) prenosi vrijeme početka 1 vrijeme završetka u daljinski brojač (RM) zahtijevajući prijenos navedenih periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju od navedenog vremena početka do završetka.
The pharmaceutical composition for use of claim 25, wherein the pulmonary disease or disorder is selected from at least one of asthma, COPD, chronic bronchitis, emphysema, bronchiectasis, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pulmonary hypertension, pulmonary vasoconstriction, pulmonary inflammation associated with cystic fibrosis, and pulmonary obstruction associated with cystic fibrosis. 
Ko-suspenzija namijenjena upotrebi u skladu s patentnim zahtjevom 20, naznačena time što se plućna bolest ili poremećaj bira između najmanje jednog od astme, COPD, pogoršanja preosjetljivosti dišnih puteva kao posljedice terapije drugim lijekom, alergijskog rinitisa, sinusitisa, plućne vazokonstrikcije, upale, alergija, otežanog disanja, respiratornog distresnog sindroma, plućne hipertenzije, te upale pluća i opstrukcije povezane s cističnom fibrozom.